Company intelligence / Profile preview
Hillhurst Biopharmaceuticals
San Diego, California, United Stateshillhurstbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hillhurst has completed a successful Phase 1 trial of its lead candidate HBI‑002, demonstrating safety and oral delivery in healthy volunteers. The company is currently conducting a Phase IIa study in patients with sickle cell disease, scheduled to complete later in 2025. Preclinical studies show efficacy for Parkinson's and doxorubicin-induced cardiotoxicity. Additional programs are advancing toward the clinic.[7][8]
- Therapeutic areas
- CardiovascularNephrologyOphthalmologyHematologyNeurology
- Modalities
- Small molecules (liquid formulations of therapeutic gases such as carbon monoxide and nitrous oxide)[1][3][8]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Hillhurst Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hillhurst Biopharmaceuticals.